Skip to main
SKIN
SKIN logo

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health's financial performance in the fourth quarter of 2023 showcased a revenue achievement of $96.8 million, surpassing both previous estimates and market expectations. This growth was primarily propelled by an increase in consumables, while the average selling price of their systems rose approximately 20% quarter-over-quarter to $28.8K, exceeding earlier projections. Additionally, the notable shift towards a higher percentage of direct sales positively impacted the overall revenue metrics, reflecting a strong demand for the company's innovative aesthetic technologies and products.

Bears say

The Beauty Health Company reported a significant decline in new core delivery system placements, with a drop of over 30% year-over-year and quarter-over-quarter to just 1,210 units, which is concerning as these placements are critical for driving future consumables sales necessary for profitability. Management's guidance for Q1 2024 indicates anticipated sales of $80 million and an adjusted EBITDA loss of approximately $7.5 million, which falls substantially short of previous estimates and raises concerns about the company's ability to reach positive EBITDA targets of $40 million for the full year. Furthermore, risks associated with brand integrity, macroeconomic challenges, a weaker upgrade cycle for the Syndeo device, and competition may hinder the company's growth prospects and overall market performance.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.